Merck & Co., Inc. Stock Soars 5.24% at Close, Boosted by Cancer Treatment Approval

Market Dynamics and Weekly Performance

Merck & Co., Inc. closed on Tuesday at $105.66, marking a 5.24% gain for the day. This upward movement was accompanied by sustained market activity, with 21.9 million shares traded, representing 0.88% of the group's market capitalization. This volume of exchanges indicates active investor participation in this progression. On a weekly basis, the stock has shown a much broader performance, accumulating a 9.57% increase since the beginning of the week. Tuesday was the peak of this bullish sequence, following a series of positive developments in previous days. This acceleration highlights the changing dynamics observed in the stock recently. On an annual perspective, Merck & Co., Inc.'s performance remains more moderate. Since the beginning of 2025, the stock has risen by 4.45%, a gain still below that of the Dow Jones index, which has recorded an 11.30% increase over the same period. However, the stock's acceleration at the end of the week suggests a renewed market interest in the pharmaceutical group, occurring in a context where several major announcements regarding its therapeutic portfolio have been made recently. This recovery in momentum contrasts with the general trend of the stock observed throughout the year.

Key Developments and Strategic Moves

The gains recorded by Merck & Co., Inc. this week can be attributed to several favorable events within the group. On Friday, November 21, the Food and Drug Administration granted approval for a combined treatment for muscle-invasive bladder cancer. This regulatory decision had already triggered a 5.4% increase in the stock price on the day of its announcement, illustrating the immediate positive impact of this therapeutic validation. The stock continues to capitalize on this approval, with markets remaining attentive to the implications of this authorization for the group's oncology portfolio. Merck & Co. is continuing its external growth strategy, aiming to enhance its therapeutic capabilities. The group is set to acquire SpringWorks Therapeutics for $3.9 billion, a move intended to enrich its innovative capacities in strategic sectors. This transaction illustrates the acquisition dynamics pursued by the pharmaceutical group in a context of marked industrial consolidation. The group's schedule remains busy in the coming weeks, with several important scientific milestones. Merck & Co. will participate in the American Society of Hematology (ASH) congress from December 6 to 9 in Orlando, where the group is set to present over 20 abstracts covering various areas of hematologic tumors, a major event in the oncology sector.